研究者業績

久保田 真彰

クボタ マサアキ  (Masaaki Kubota)

基本情報

所属
千葉大学 医学部附属病院 助教
学位
博士(医学)(2022年3月 千葉大学大学院)

researchmap会員ID
R000039372

論文

 18
  • Takaki Hiwasa, Yoichi Yoshida, Masaaki Kubota, Shu-Yang Li, Bo-Shi Zhang, Tomoo Matsutani, Seiichiro Mine, Toshio Machida, Masaaki Ito, Satoshi Yajima, Mikako Shirouzu, Shigeyuki Yokoyama, Mizuki Sata, Kazumasa Yamagishi, Hiroyasu Iso, Norie Sawada, Shoichiro Tsugane, Minoru Takemoto, Aiko Hayashi, Koutaro Yokote, Yoshio Kobayashi, Kazuyuki Matsushita, Koichiro Tatsumi, Hirotaka Takizawa, Go Tomiyoshi, Hideaki Shimada, Yoshinori Higuchi
    Medicine International 4(5) 45 2024年6月19日  査読有り
  • Bo-Shi Zhang, Xiao-Meng Zhang, Masaaki Ito, Satoshi Yajima, Kimihiko Yoshida, Mikiko Ohno, Eiichiro Nishi, Hao Wang, Shu-Yang Li, Masaaki Kubota, Yoichi Yoshida, Tomoo Matsutani, Seiichiro Mine, Toshio Machida, Minoru Takemoto, Hiroki Yamagata, Aiko Hayashi, Koutaro Yokote, Yoshio Kobayashi, Hirotaka Takizawa, Hideyuki Kuroda, Hideaki Shimada, Yasuo Iwadate, Takaki Hiwasa
    International journal of molecular sciences 25(9) 2024年4月30日  
    Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima-media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.
  • Toshiki Namiki, Minoru Takemoto, Aiko Hayashi, Hiroki Yamagata, Takahiro Ishikawa, Koutaro Yokote, Shu-Yang Li, Masaaki Kubota, Bo-Shi Zhang, Yoichi Yoshida, Tomoo Matsutani, Seiichiro Mine, Toshio Machida, Yoshio Kobayashi, Jiro Terada, Akira Naito, Koichiro Tatsumi, Hirotaka Takizawa, Rika Nakamura, Hideyuki Kuroda, Yasuo Iwadate, Takaki Hiwasa
    BMC endocrine disorders 23(1) 239-239 2023年10月30日  
    BACKGROUND: Autoantibodies develop in autoimmune diseases, cancer, diabetes mellitus (DM), and atherosclerosis-related diseases. However, autoantibody biomarkers have not been successfully examined for diagnosis and therapy. METHODS: Serological identification of antigens through recombinant cDNA expression cloning (SEREX) was used for primary screening of antigens. The cDNA product was expressed in bacteria and purified. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) was used to evaluate antibody levels in serum samples. RESULTS: Phosphoenolpyruvate carboxykinase 1 (PCK1) was recognized as an antigen by serum IgG antibodies in the sera of patients with atherosclerosis. AlphaLISA showed significantly higher serum antibody levels against recombinant PCK1 protein in patients with DM and cardiovascular disease than in healthy donors, but not in those with acute ischemic stroke, transient ischemic attack, or obstructive sleep apnea syndrome. The area under the receiver operating characteristic curve for anti-PCK1 antibodies was 0.7024 for DM. The serum anti-PCK1 antibody levels were associated with age, platelet count, and blood pressure. Anti-PCK1-antibody-positive patients showed significantly lower overall survival than the negative patients. CONCLUSIONS: Serum anti-PCK1 antibody levels were found to be associated with DM. The anti-PCK1 antibody marker is useful for predicting the overall survival of patients with DM.
  • Marina Sakata, Yosuke Tajima, Masaaki Kubota, Yasuo Iwadate
    Radiology Case Reports 18(10) 3453-3456 2023年10月  
  • Shu-Yang Li, Yoichi Yoshida, Masaaki Kubota, Bo-Shi Zhang, Tomoo Matsutani, Masaaki Ito, Satoshi Yajima, Kimihiko Yoshida, Seiichiro Mine, Toshio Machida, Aiko Hayashi, Minoru Takemoto, Koutaro Yokote, Mikiko Ohno, Eiichiro Nishi, Kenichiro Kitamura, Ikuo Kamitsukasa, Hirotaka Takizawa, Mizuki Sata, Kazumasa Yamagishi, Hiroyasu Iso, Norie Sawada, Shoichiro Tsugane, Katsuro Iwase, Hideaki Shimada, Yasuo Iwadate, Takaki Hiwasa
    Frontiers in cardiovascular medicine 10 1042272-1042272 2023年  
    INTRODUCTION: Autoantibodies against inflammatory cytokines may be used for the prevention of atherosclerosis. Preclinical studies consider colony-stimulating factor 2 (CSF2) as an essential cytokine with a causal relationship to atherosclerosis and cancer. We examined the serum anti-CSF2 antibody levels in patients with atherosclerosis or solid cancer. METHODS: We measured the serum anti-CSF2 antibody levels via amplified luminescent proximity homogeneous assay-linked immunosorbent assay based on the recognition of recombinant glutathione S-transferase-fused CSF2 protein or a CSF2-derived peptide as the antigen. RESULTS: The serum anti-CSF2 antibody (s-CSF2-Ab) levels were significantly higher in patients with acute ischemic stroke (AIS), acute myocardial infarction (AMI), diabetes mellitus (DM), and chronic kidney disease (CKD) compared with healthy donors (HDs). In addition, the s-CSF2-Ab levels were associated with intima-media thickness and hypertension. The analyzes of samples obtained from a Japan Public Health Center-based prospective study suggested the utility of s-CSF2-Ab as a risk factor for AIS. Furthermore, the s-CSF2-Ab levels were higher in patients with esophageal, colorectal, gastric, and lung cancer than in HDs but not in those with mammary cancer. In addition, the s-CSF2-Ab levels were associated with unfavorable postoperative prognosis in colorectal cancer (CRC). In CRC, the s-CSF2-Ab levels were more closely associated with poor prognosis in patients with p53-Ab-negative CRC despite the lack of significant association of the anti-p53 antibody (p53-Ab) levels with the overall survival. CONCLUSION: S-CSF2-Ab was useful for the diagnosis of atherosclerosis-related AIS, AMI, DM, and CKD and could discriminate poor prognosis, especially in p53-Ab-negative CRC.

MISC

 28

講演・口頭発表等

 17